Skip to main content

Table 1 Clinical and demographic characteristics of the cohort

From: Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients

  Not on Anticoagulation On anticoagulation p value
Total number of patients 828 120  
Age (years)    < 0.0001
 Mean (SD) 62.0 (13.9) 70.5 (11.6)  
 Range 20.4–94.2 31.7–94.6  
Sex    0.50
 Female 372 (44.9) 50 (41.7)  
 Male 456 (55.1) 70 (58.3)  
ECOG    0.0001
 0 447 (54.0) 43 (35.8)  
 1 290 (35.0) 54 (45.0)  
 ≥ 2 60 (7.2) 20 (16.7)  
 Unknown 31 (3.7) 3 (2.5)  
Primary tumor    < 0.0001
 Melanoma 417 (50.4) 48 (40.0)  
 Lung 139 (16.8) 40 (33.3)  
 Other 272 (32.9) 32 (26.7)  
Stage    0.56
 III 149 (18.0) 19 (15.8)  
 IV 679 (82.0) 101 (84.2)  
Treatment regimen    0.002
 Anti-CTLA-4 166 (20.0) 9 (7.4)  
 Anti-PD-1 or Anti-PD-L1 497 (60.0) 93 (77.5)  
 Anti-PD-1 + Anti-CTLA-4 165 (19.9) 18 (15.0)  
Treatment line    0.75
 First 632 (76.3) 90 (75.0)  
 Non-first 196 (23.7) 30 (25.0)  
Immunotherapy alone or in combination with other therapy    0.19
 Alone 632 (76.3) 85 (70.8)  
 With other therapy 196 (23.7) 35 (29.2)  
Alive status    0.11
 Alive 381 (46.0) 46 (38.3)  
 Deceased 447 (54.0) 74 (61.7)